- Letter to the Editor
- Open Access
Response to the Letter to the Editor by Rob Armstrong
© The Author(s). 2017
- Received: 5 April 2017
- Accepted: 18 April 2017
- Published: 26 April 2017
In a recent Letter to the Editor, Armstrong raises concern that the design of the study reported by Six et al. was not consistent with the product label for treatment of Amblyomma americanum, since fluralaner was not re-administered 56 days after the initial treatment. The Authors disagree with this assessment and confirm that the design was appropriate, and therefore the results and conclusions for the entire study period are valid.
- Entire Study Period
- Tick Species
- Product Label
- Monthly Dose
- Tick Feeding
Six et al. reported the results of a study demonstrating that monthly administration of sarolaner consistently killed significantly more A. americanum ticks within 24 h than a single dose of fluralaner from 6 weeks after initial treatment . In his Letter to the Editor, Armstrong raised concern that the efficacy of fluralaner was evaluated at times outside the label administration recommendations .
The author states that the approved Bravecto® label requires that fluralaner be re-administered at 56 days for the treatment A. americanum when in fact the label [3, 4] states that fluralaner may be re-administered every 8 weeks in case of potential exposure to A. americanum (although the general dosing directions state fluralaner should be administered every 12 weeks). This language is very confusing and may be interpreted by a pet owner or veterinarian to mean that fluralaner may be effective against A. americanum for up to 12 weeks. This supports the study design which evaluated efficacy for 12 weeks and therefore we believe the results and conclusions for the entire study period are valid.
The author states that the manuscript reports in the Discussion section that the Bravecto® label directions were not followed when in fact the Discussion section simply references the efficacy of fluralaner against A. americanum as reported in the Bravecto® Freedom of Information Summary ; the design of the study (a single dose of fluralaner compared to 3 monthly doses of Simparica® over a 90 day period) is clearly stated in the Methods section of the Abstract.
The author accurately summarizes the manuscript which reported that at the 8 and 12 h counts on Day 42 the efficacy of both products was lower than expected for unknown reason; however, at the 24 h count on Day 42 and for the duration of the study through Day 90, sarolaner provided significantly lower live tick counts compared to fluralaner (P ≤ 0.0006) .
The design, conduct and reporting of this study are therefore accurate and appropriate. Under the conditions of this study, monthly administration of Simparica® provided consistently high (> 70%) efficacy against A. americanum within 24 h of re-infestations over the 3-month (3 dose) period and from Day 42 onwards this efficacy was significantly better than that provided by fluralaner.
Veterinarians and pet owners cannot predict at the time of treatment the genera and species of tick to which a dog will potentially be exposed. This consideration is of even greater importance when a long-acting product (where the tick genera and species must be predicted months in advance) is used. With Bravecto® this is further complicated by the fact that the duration of efficacy and therefore the ideal treatment interval varies depending upon the tick species. The design of the study is consistent with the fluralaner re-treatment interval recommended on the product label (anywhere between 8 and 12 weeks), and demonstrates the efficacy observed under controlled conditions from a re-treatment interval that will possibly be used on dogs exposed to A. americanum.
This study therefore clearly demonstrates that the rapid and consistent kill of A. americanum provided by monthly dosing with Simparica® will reduce the direct deleterious effects of tick feeding and should reduce the risk of tick-borne disease transmission better, and more reliably than a single dose of fluralaner over a 90-day period.
The authors would like to thank Steven Maeder for his assistance in preparing this Letter.
This study was funded by Zoetis, Parsippany, NJ.
Availability of data and materials
Data upon which conclusions are based were presented in the paper.
All authors assisted with the design and conduct of the study, interpretation of the data, and manuscript review. DRY conducted the study, which was monitored by MRM. SPM conducted the statistical analyses. All authors read and approved the final version of the manuscript and this letter.
This study was funded by Zoetis, Florham Park, NJ. RHS, MRM and SPM are current employees of Zoetis. DRY was an investigator contracted for this study.
Consent for publication
The protocol was reviewed and approved by the YVRS Institutional Animal Care and Use Committee prior to implementation.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Six RH, Young DR, Myers MR, Mahabir SP. Comparative speed of kill of sarolaner (Simparica™ Chewables) and fluralaner (Bravecto®) against induced infestations of Amblyomma americanum on dogs. Parasit Vectors. 2016;9:399.View ArticlePubMedPubMed CentralGoogle Scholar
- Armstrong R. The conclusion of a comparative efficacy study of fluralaner and sarolaner against the tick Amblyomma americanum on dogs is based on results obtained at study times that are outside the fluralaner label recommendations. Parasit Vectors. 2017;10:159.View ArticlePubMedPubMed CentralGoogle Scholar
- FDA, Package Insert. BRAVECTO. http://us.bravecto.com/pdfs/bravecto_pi_mah.pdf. Accessed 29 Sept 2016.
- FDA, FOI. NADA 141–426. BRAVECTO. http://www.fda.gov/downloads/animalveterinary/products/approvedanimaldrugproducts/foiadrugsummaries/ucm399075.pdf. Accessed 20 Aug 2016.